X

Trial Profile

A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bleomycin; Cisplatin; Etoposide; Filgrastim; Ifosfamide
Indications Germ cell and embryonal neoplasms
Focus Therapeutic Use

Most Recent Events

24 Sep 2012 Biomarkers information updated
20 Oct 2011 Status changed from active, no longer recruiting to completed.
08 Jun 2010 Results presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com